Page 3 - Thorac Oncol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study

One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Lopes pegnaNational healthCentral committeeLancet public healthValue health regCouncil gazette issue noRisk index working groupInternational agency for research on cancerNational bureau of statistics chinaNational act planCouncil of the people republic chinaFamily planning commission of chinaBull world health organHarvard centerLancet glob healthNational comprehensive cancer network

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Twyman saint victorBernabe caroEnglj medThorac oncolCancer resClin oncolRespir med

Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica s Microbiome-Based Immuno-Oncology Drug

/PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd..

Laine yonkerRuth peretsRivka neufeldJoseph greenElran haberSloan ketteringLavie bio ltdBiomica ltdEvogene ltdIsrael ministry of healthEdison groupResearch centersRambam healthCasterra ag ltdCanonic ltdJohn hopkins medical center

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Le chevalierCollaborative groupNational comprehensive cancer networkManag resOpin oncolCancer staging projectThorac oncolEnglj medClin oncolலெ செவாலியர்கூட்டு குழுதேசிய விரிவான புற்றுநோய் வலைப்பின்னல்புற்றுநோய் அரங்கு ப்ராஜெக்ட்

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United statesLe chevalierEuropean organization for researchJapan oncology groupJapan lung cancer societyEnglj medRev clin oncolClin oncolEuropean organizationNatl cancer instLife questionnaireThorac oncolNational hospital organization study groupLung cancerSouthern california regional cancer registryWest japan oncology group